$ボルコム・インク (VLCN.US)$ As predicted on 8 Oct and premarket up 20%

$プロタゴニスト・セラピューティクス (PTGX.US)$
Protagonist Therapeutics Announces Removal Of FDA Clinical Hold On The Rusfertide Clinical Development Program

$ナノビリサイズ (NNVC.US)$
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 was found to be effective against SARS-CoV-2 in a standard cell culture pseudovirion assay, demonstrating that the drug indeed has broad-spectrum pan-coronavirus activity. This pan-coronavirus activity implies that the drug NV-CoV-2 should remain active in spite of evolution of variants of SARS-CoV-2 in the field, a highly sought-after characteristic to combat the current global pandemic.
In this assay, both the drug candidate NV-CoV-2 and a positive control antibody specific to the Spike antigen S1 of the SARS-CoV-2 virus suppressed the infection by the SARS-CoV-2-pseudovirions in cell culture studies to virtually the same baseline levels.
We have now demonstrated that NV-CoV-2 is highly effective in cell cultures against SARS-CoV-2, human coronavirus NL-63, and human coronavirus 229E, all very different human coronaviruses. These results imply that the drug will remain active in spite of novel variants of SARS-CoV-2 evolution in the field, and indeed demonstrate the pan-coronavirus activity of our clinical drug candidate NV-CoV-2.
Additionally, the pseudovirion study also showed that NV-CoV-2 neutralizes the virus particles themselves, outside of the cells, validating our design mechanism.

$Adamas Pharmaceuticals (ADMS.US)$
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). The first CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late fourth quarter 2021 or in early first quarter 2022.
The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, the first and only U.S. Food and Drug Administration (FDA)-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy; and Osmolex ER (amantadine) extended release tablets, approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
"This acquisition represents a significant step to further build a strong and diverse Parkinson's disease portfolio, and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "We have a proven track record of strong commercial execution, and look forward to building on GOCOVRI's growth momentum so that more patients can benefit from access to Adamas' innovative neurological therapies."

stock related to bitcoin gonna be green if btc stay above 56k
$スフィア3D・コーポ (ANY.US)$
$ビット・デジタル (BTBT.US)$
$BITマイニング (BTCM.US)$

今日の2つの潜在的な株式
$ダットチャット・インク (DATS.US)$
$エア・テスト・システムズ (AEHR.US)$

$ボイジャー・セラピューティクス (VYGR.US)$
$ボルコム・インク (VLCN.US)$
both green

2 potential stock today
$エス・エヌ・ディー・エル (SNDL.US)$
$ヴァクスアート (VXRT.US)$

ああ、そうだな...
$スフィア3D・コーポ (ANY.US)$

この3株は寄り付き前に緑だった
$ニューロメトリックス (NURO.US)$
$ボルコム・インク (VLCN.US)$
$ボイジャー・セラピューティクス (VYGR.US)$